Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 diabetic
Treated with OHA (oral hypoglycaemic agent monotherapy for at least 3 months. Prior use of metformin is allowed
Body Mass Index (BMI) between 27.0-42.0 kg/m\^2 (inclusive)
HbA1c maximum 10% based on analysis from central laboratory
You may not be if
Cardiac problems
Uncontrolled treated/untreated hypertension
Proliferative retinopathy or known autonomic neuropathy
Recurrent severe hypoglycemia as judged by the investigator
Known or suspected allergy to trial product or related products
Use of any drug (except for OHAs), which in the investigators opinion could interfere with the glucose level or body weight or any contraindication to metformin use or intolerance to metformin 1000 mg (prior to trial entry or during run-in period). Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
Known or suspected abuse of alcohol or narcotics
Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
TSH (thyroid stimulating hormone) below 0.2 or above 15 U/mL
Type 1 or other specific causes of diabetes
Clareo Health | Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
